B type natriuretic peptide - A diagnostic breakthrough in peri-operative cardiac risk assessment?

Anaesthesia

Volumn 64, Issue 2, 2009, Pages 165-178

  Rodseth, R N ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ACUTE CORONARY SYNDROME; AMINO TERMINAL SEQUENCE; ANESTHESIA; BODY MASS; CARDIOMYOPATHY; CARDIOVASCULAR RISK; DIAGNOSTIC PROCEDURE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART SURGERY; HEART VENTRICLE HYPERTROPHY; HUMAN; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; MYOCARDITIS; PERICARDITIS; PERIOPERATIVE COMPLICATION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; VALVULAR HEART DISEASE; AGED; BLOOD; HEART DISEASE; METHODOLOGY; MIDDLE AGED; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PROGNOSIS; REFERENCE VALUE;

AGED; ANESTHESIA; BIOLOGICAL MARKERS; HEART DISEASES; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT;

EID: 59449087350     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2008.05689.x     Document Type: Review

References (141)

1. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116: 1971-96.
2. Falcone RA, Nass C, Jermyn R, et al. The value of preoperative pharmacologic stress testing before vascular surgery using ACC/AHA guidelines: a prospective, randomized trial. Journal of Cardiothoracic and Vascular Anesthesia 2003; 17: 694-8.
3. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. New England Journal of Medicine 2004; 351: 2795-804.
4. Wiesbauer F, Schlager O, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity: a systematic review and meta-analysis. Anesthesia and Analgesia 2007; 104: 27-41.
5. Mangano DT. Perioperative cardiac morbidity. Anesthesiology 1990; 72: 153-84.
6. Hammill BG, Curtis LH, Bennett-Guerrero E, et al. Impact of heart failure on patients undergoing major noncardiac surgery. Anesthesiology 2008; 108: 559-67.
7. Hernandez AF, Whellan DJ, Stroud S, Sun JL, O'Connor CM, Jollis JG. Outcomes in heart failure patients after major noncardiac surgery. Journal of the American College of Cardiology 2004; 44: 1446-53.
8. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. New England Journal of Medicine 1977; 297: 845-50.
9. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100: 1043-9.
10. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Journal of the American College of Cardiology 1996; 27: 910-48.
11. Fonseca C, Morais H, Mota T, et al. The diagnosis of heart failure in primary care: value of symptoms and signs. European Journal of Heart Failure 2004; 6: 795-800, 21-2.
12. Azevedo A, Bettencourt P, Pimenta J, et al. Clinical syndrome suggestive of heart failure is frequently attributable to non-cardiac disorders - population-based study. European Journal of Heart Failure 2007; 9: 391-6.
13. McCullough PA. B-type natriuretic peptides. A diagnostic breakthrough in heart failure. Minerva Cardioangiologica 2003; 51: 121-9.
14. de Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. Chest 2004; 125: 652-68.
15. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. Journal of Hypertension 1992; 10: 907-12.
16. Gardner DG, Chen S, Glenn DJ, Grigsby CL. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 2007; 49: 419-26.
17. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovascular Research 2006; 69: 318-28.
18. Hystad ME, Geiran OR, Attramadal H, et al. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiologica Scandinavica 2001; 171: 395-403.
19. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circulation Research 2002; 91: 1127-34.
20. Goetze JP, Gore A, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. The FASEB Journal 2004; 18: 1928-30.
21. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. European Journal of Heart Failure 2004; 6: 257-60.
22. Durocher D, Grepin C, Nemer M. Regulation of gene expression in the endocrine heart. Recent Progress in Hormone Research 1998; 53: 7-23; discussion 2-3.
23. Maack T, Suzuki M, Almeida FA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238: 675-8.
24. Wu AH, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro-and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. The American Journal of Cardiology 2003; 92: 628-31.
25. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. American Journal of Physiology 1998; 274: H1684-9.
26. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. New England Journal of Medicine 1998; 339: 321-8.
27. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992; 86: 1081-8.
28. Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. American Journal of Kidney Diseases 2000; 36: 767-74.
29. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. New England Journal of Medicine 1997; 336: 828-34.
30. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293: 1900-5.
31. Munger MA, Ng TM, Van Tassell BW. Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment. Pharmacotherapy 2007; 27: 619-25.
32. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. British Journal of Clinical Pharmacology 1997; 43: 329-32.
33. Barber MN, Kanagasundaram M, Anderson CR, Burrell LM, Woods RL. Vascular neutral endopeptidase inhibition improves endothelial function and reduces intimal hyperplasia. Cardiovascular Research 2006; 71: 179-88.
34. Richards M, Nicholls MG, Espiner EA, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. Journal of the American College of Cardiology 2006; 47: 52-60.
35. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Reviews in Cardiovascular Medicine 2003; 4 (Suppl. 4): S13-9.
36. Ng LL, Loke IW, Davies JE, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. Journal of the American College of Cardiology 2005; 45: 1043-50.
37. Austin WJ, Bhalla V, Hernandez-Arce I, et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. American Journal of Clinical Pathology 2006; 126: 506-12.
38. Daniels LB, Allison MA, Clopton P, et al. Use of natriuretic peptides in pre-participation screening of college athletes. International Journal of Cardiology 2008; 124: 411-14.
39. Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? European Heart Journal 2005; 26: 2269-76.
40. Alehagen U, Goetze JP, Dahlstrom U. Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. Clinica Chimica Acta 2007; 382: 8-14.
41. Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. Journal of the American College of Cardiology 2007; 49: 109-16.
42. Sarzani R, Dessi-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. Journal of Endocrinological Investigation 1996; 19: 581-5.
43. Dessi-Fulgheri P, Sarzani R, Tamburrini P, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. Journal of Hypertension 1997; 15: 1695-9.
44. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005; 112: 2163-8.
45. Nishikimi T, Yoshihara F, Morimoto A, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22-30.
46. Karagiannis A, Tziomalos K, Zamboulis C. Plasma B-type natriuretic peptide is related to left ventricular mass in hypertensive patients. European Heart Journal 2004; 25: 1967.
47. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Biochemical diagnosis of impaired left ventricular ejection fraction - comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Clinical Chemistry and Laboratory Medicine 2004; 42: 159-63.
48. Tsutamoto T, Sakai H, Nishiyama K, et al. Direct comparison of transcardiac increase in brain natriuretic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure. Circulation Journal 2007; 71: 1873-8.
49. Chien TI, Chen HH, Kao JT. Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP. Clinica Chimica Acta 2006; 369: 95-9.
50. Hammerer-Lercher A, Puschendorf B, Mair J. Cardiac natriuretic peptides: new laboratory parameters in heart failure patients. Clinical Laboratory 2001; 47: 265-77.
51. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normalman. The Journal of Clinical Endocrinology and Metabolism 1993; 76: 91-6.
52. Mair J, Falkensammer G, Poelzl G, Hammerer-Lercher A, Griesmacher A, Pachinger O. B-type natriuretic peptide (BNP) is more sensitive to rapid hemodynamic changes in acute heart failure than N-terminal proBNP. Clinica Chimica Acta 2007; 379: 163-6.
53. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. Journal of the American College of Cardiology 2006; 47: 345-53.
54. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clinical Chemistry 2006; 52: 1528-38.
55. Sakai H, Tsutamoto T, Ishikawa C, et al. Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP secretion and extent of coronary artery stenosis in patients with stable coronary artery disease. Circulation Journal 2007; 71: 499-505.
56. Moe GW, Howlett J, Januzzi JL, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115: 3103-10.
57. Korenstein D, Wisnivesky JP, Wyer P, Adler R, Ponieman D, McGinn T. The utility of B-type natriuretic peptide in the diagnosis of heart failure in the emergency department: a systematic review. BMC Emergency Medicine 2007; 7:6.
58. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emer gency diagnosis of heart failure. New England Journal of Medicine 2002; 347: 161-7.
59. Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Reviews in Cardiovascular Medicine 2002; 3 (Suppl. 4): S10-7.
60. Gibler WB, Blomkalns AL, Collins SP. Evaluation of chest pain and heart failure in the emergency department: impact of multimarker strategies and B-type natriuretic peptide. Reviews in Cardiovascular Medicine 2003; 4 (Suppl. 4): S47-55.
61. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. The American Journal of Cardiology 2005; 95: 948-54.
62. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New England Journal ofMedicine 2004; 350: 655-63.
63. Cuthbertson BH, Amiri AR, Croal BL, Rajagopalan S, Brittenden J, Hillis GS. Utility of B-type natriuretic peptide in predicting medium-term mortality in patients undergoing major non-cardiac surgery. The American Journal of Cardiology 2007; 100: 1310-3.
64. van Kimmenade RR, Pinto YM, Bayes-Genis A, Lainchbury JG, Richards AM, Januzzi JL Jr. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. The American Journal of Cardiology 2006; 98: 386-90.
65. Arbab-Zadeh A, Dijk E, Prasad A, et al. Effect of aging and physical activity on left ventricular compliance. Circulation 2004; 110: 1799-805.
66. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. American Journal of Kidney Diseases 2003; 41: 571-9.
67. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. Journal of the American College of Cardiology 2002; 40: 976-82.
68. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. European Heart Journal 2006; 27: 330-7.
69. Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. The American Journal of Cardiology 2008; 101: 29-38.
70. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330: 625.
71. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
72. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. Journal of the American College of Cardiology 2007; 49: 1733-9.
73. Valle R, Aspromonte N, Giovinazzo P, et al. B-type natriuretic Peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure. Journal of Cardiac Failure 2008; 14: 219-24.
74. Cochet A, Zeller M, Cottin Y, et al. The extent of myocardial damage assessed by contrast-enhanced MRI is a major determinant of N-BNP concentration after myocardial infarction. European Journal of Heart Failure 2004; 6: 555-60.
75. Ceriani L, Giovanella L. Cardiac natriuretic peptides after myocardial infarction: relationship with infarct size, left ventricular function and remodelling assessed by 99mTc- sestamibi gated-single photon emission tomography. Clinical Chemistry and Laboratory Medicine 2007; 45: 226-31.
76. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921-9.
77. Cerisano G, Pucci PD, Sulla A, et al. Relation between plasma brain natriuretic peptide, serum indexes of collagen type I turnover, and left ventricular remodeling after reperfused acute myocardial infarction. The American Journal of Cardiology 2007; 99: 651-6.
78. Bassan R, Potsch A, Maisel A, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. European Heart Journal 2005; 26: 234-40.
79. Brown A, George J, Murphy MJ, Struthers A. Could BNP screening of acute chest pain cases lead to safe earlier discharge of patients with non-cardiac causes? A pilot study. QJM 2007; 100: 755-61.
80. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004; 110: 3206-12.
81. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. Journal of the American College of Cardiology 2002; 40: 437-45.
82. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106: 2913-8.
83. James SK, Lindback J, Tilly J, et al. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. Journal of the American College of Cardiology 2006; 48: 1146-54.
84. Steen H, Futterer S, Merten C, Junger C, Katus HA, Giannitsis E. Relative role of NT-pro BNP and cardiac troponin T at 96 hours for estimation of infarct size and left ventricular function after acute myocardial infarction. Journal of Cardiovascular Magnetic Resonance 2007; 9:749-58.
85. Jernberg T, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. Journal of the American College of Cardiology 2003; 42: 1909-16.
86. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. New England Journal of Medicine 2005; 352: 666-75.
87. Schnabel R, Lubos E, Rupprecht HJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. Journal of the American College of Cardiology 2006; 47: 552-8.
88. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
89. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004; 109: 3176-81.
90. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002; 87: 131-5.
91. Fuat A, Murphy JJ, Hungin AP, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. The British Journal of General Practice 2006; 56: 327-33.
92. Rao A, Hodgson L, Pearce D, Walsh J. BNP in the community - still work to be done. International Journal of Cardiology 2008; 124: 228-30.
93. Illango RK. Utilizing NT-proBNP in the selection of risks for life insurance. Journal of Insurance Medicine 2007; 39: 182-91.
94. Roch A. What does high NT-proBNP mean in septic shock patients? A part of the puzzle. Critical Care 2007; 11: 122.
95. Mokart D, Sannini A, Brun JP, et al. N-terminal pro-brain natriuretic peptide as an early prognostic factor in cancer patients developing septic shock. Critical Care 2007; 11: R37.
96. Phua J, Lim TK, Lee KH. B-type natriuretic peptide: issues for the intensivist and pulmonologist. Critical Care Medicine 2005; 33: 2094-13.
97. Omland T. Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. Critical Care Medicine 2008; 36: S17-27.
98. Longhitano S, Coriat P, Agro F. Postoperative myocardial infarction: pathophysiology, new diagnostic criteria, prevention. Minerva Anestesiologica 2006; 72: 965-83.
99. Dernellis J, Panaretou M. Assessment of cardiac risk before non-cardiac surgery: brain natriuretic peptide in 1590 patients. Heart 2006; 92: 1645-50.
100. Yeh HM, Lau HP, Lin JM, Sun WZ, Wang MJ, Lai LP. Preoperative plasma N-terminal pro-brain natriuretic peptide as a marker of cardiac risk in patients undergoing elective non-cardiac surgery. The British Journal of Surgery 2005; 92: 1041-5.
101. Gibson SC, Payne CJ, Byrne DS, Berry C, Dargie HJ, Kingsmore DB. B-type natriuretic peptide predicts cardiac morbidity and mortality after major surgery. The British Journal of Surgery 2007; 94: 903-9.
102. Cuthbertson BH, Amiri AR, Croal BL, et al. Utility of B-type natriuretic peptide in predicting perioperative cardiac events in patients undergoing major non-cardiac surgery. British Journal of Anaesthesia 2007; 99: 170-6.
103. Cuthbertson BH, Card G, Croal BL, McNeilly J, Hillis GS. The utility of B-type natriuretic peptide in predicting postoperative cardiac events and mortality in patients undergoing major emergency non-cardiac surgery. Anaesthesia 2007; 62: 875-81.
104. Berry C, Kingsmore D, Gibson S, et al. Predictive value of plasma brain natriuretic peptide for cardiac outcome after vascular surgery. Heart 2006; 92: 401-2.
105. Feringa HH, Bax JJ, Elhendy A, et al. Association of plasma N-terminal pro-B-type natriuretic peptide with postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass. The American Journal of Cardiology 2006; 98: 111-5.
106. Feringa HH, Schouten O, Dunkelgrun M, et al. Plasma N-terminal pro-B-type natriuretic peptide as long-term prognostic marker after major vascular surgery. Heart 2007; 93: 226-31.
107. Mahla E, Baumann A, Rehak P, et al. N-terminal pro-brain natriuretic peptide identifies patients at high risk for adverse cardiac outcome after vascular surgery. Anesthesiology 2007; 106: 1088-95.
108. Goei D, Schouten O, Boersma E, et al. Influence of renal function on the usefulness of N-terminal pro-B-type natriuretic peptide as a prognostic cardiac risk marker in patients undergoing noncardiac vascular surgery. The American Journal of Cardiology 2008; 101: 122-6.
109. Leibowitz D, Planer D, Rott D, Elitzur Y, Chajek-Shaul T, Weiss AT. Brain Natriuretic Peptide Levels Predict Perioperative Events in Cardiac Patients Undergoing Noncardiac Surgery: A Prospective Study. Cardiology 2007; 110: 266-70.
110. Rodseth RN, Padayachee L, Biccard BM. A meta-analysis of the utility of pre-operative brain natriuretic peptide in predicting early and intermediate-term mortality and major adverse cardiac events in vascular surgical patients. Anaesthesia 2008; 63: 1226-1233.
111. Watanabe M, Murakami M, Furukawa H, Nakahara H. Is measurement of plasma brain natriuretic peptide levels a useful test to detect for surgical timing of valve disease? International Journal of Cardiology 2004; 96: 21-4.
112. Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004; 109: 2302-8.
113. Eliasdottir SB, Klemenzson G, Torfason B, Valsson F. Brain natriuretic peptide is a good predictor for outcome in cardiac surgery. Acta Anaesthesiologica Scandinavica 2008; 52: 182-7.
114. Hutfless R, Kazanegra R, Madani M, et al. Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. Journal of the American College of Cardiology 2004; 43: 1873-9.
115. Jeong DS, Kim KH, Kim CY, Kim JS. Relationship between plasma B-type natriuretic peptide and ventricular function in adult cardiac surgery patients. The Journal of International Medical Research 2008; 36: 31-9.
116. Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004; 110: 124-7.
117. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.
118. Jourdain P, Funck F, Bellorini M, et al. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. European Journal of Heart Failure 2003; 5: 155-60.
119. Kertai MD, Boersma E, Bax JJ, et al. A meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery. Heart 2003; 89: 1327-34.
120. Messer PB, Singh R, McAuley FT, Handley G, Peaston B, Snowden CP. The use of N-terminal pro-B type natriuretic peptide in a pre-operative setting to predict left ventricular systolic dysfunction on echocardiogram. Anaesthesia 2008; 63: 482-7.
121. O'Hanlon R, O'Shea P, Ledwidge M, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. Journal of Cardiac Failure 2007; 13: 50-5.
122. Suttner S, Lang K, Piper SN, Schultz H, Rohm KD, Boldt J. Continuous intra- and postoperative thoracic epidural analgesia attenuates brain natriuretic peptide release after major abdominal surgery. Anesthesia and Analgesia 2005; 101: 896-903.
123. Adesanya AO, de Lemos JA, Greilich NB, Whitten CW. Management of perioperative myocardial infarction in noncardiac surgical patients. Chest 2006; 130: 584-96.
124. DeFilippi C, van Kimmenade RR, Pinto YM. Aminoterminal pro-B-type natriuretic peptide testing in renal disease. The American Journal of Cardiology 2008; 101: 82-8.
125. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
126. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. Journal of the American College of Cardiology 2001; 38: 789-95.
127. Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. The American Journal of Cardiology 2003; 91: 891-4.
128. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. Journal of the American College of Cardiology 2006; 47: 85-90.
129. Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) sub- study. American Heart Journal 2005; 149: 744-50.
130. Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Archives of Internal Medicine 2007; 167: 400-7.
131. Daniels LB, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. American Heart Journal 2006; 151: 999-1005.
132. Ridley S. Cardiac scoring systems - what is their value? Anaesthesia 2003; 58: 985-91.
133. Knudsen CW, Clopton P, Westheim A, et al. Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study. Annals of Emergency Medicine 2005; 45: 573-80.
134. van Kimmenade RR, Pinto YM, Januzzi JL Jr. Importance and interpretation of intermediate (gray zone) amino- terminal pro-B-type natriuretic peptide concentrations. The American Journal of Cardiology 2008; 101: 39-42.
135. Baggish AL, van Kimmenade RR, Januzzi JL Jr. The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. The American Journal of Cardiology 2008; 101: 43-8.
136. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-235.
137. Bayes-Genis A, DeFilippi C, Januzzi JL Jr. Understanding amino-terminal pro-B-type natriuretic peptide in obesity. The American Journal of Cardiology 2008; 101: 89-94.
138. Masson S, Latini R. Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure. The American Journal of Cardiology 2008; 101: 56-60.
139. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. American Heart Journal 1999; 138: 1126-32.
140. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. Journal of the American College of Cardiology 2001; 37: 386-91.
141. Richards M, Troughton RW. NT-proBNP in heart failure: therapy decisions and monitoring. European Journal of Heart Failure 2004; 6: 351-4.